GeneDx Holdings Corp. (NASDAQ:WGS) Given Average Rating of “Moderate Buy” by Analysts

GeneDx Holdings Corp. (NASDAQ:WGS) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $138.1250.

A number of analysts recently issued reports on WGS shares. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Guggenheim reaffirmed a “buy” rating and set a $170.00 target price (up previously from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Wall Street Zen raised shares of GeneDx from a “hold” rating to a “buy” rating in a report on Saturday. Wells Fargo & Company set a $155.00 price objective on shares of GeneDx and gave the company an “equal weight” rating in a research note on Monday, December 15th. Finally, BTIG Research upped their target price on shares of GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, December 12th.

Insider Buying and Selling

In other news, CEO Katherine Stueland sold 10,857 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $143.89, for a total transaction of $1,562,213.73. Following the sale, the chief executive officer owned 14,237 shares in the company, valued at approximately $2,048,561.93. This trade represents a 43.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Kevin Feeley sold 3,855 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $143.87, for a total transaction of $554,618.85. Following the completion of the transaction, the chief financial officer owned 8,731 shares of the company’s stock, valued at $1,256,128.97. This trade represents a 30.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 59,587 shares of company stock worth $9,177,338. Insiders own 29.60% of the company’s stock.

Institutional Trading of GeneDx

Several hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its position in GeneDx by 30.2% during the 1st quarter. Royal Bank of Canada now owns 29,479 shares of the company’s stock valued at $2,611,000 after buying an additional 6,840 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of GeneDx by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,641 shares of the company’s stock valued at $677,000 after acquiring an additional 453 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of GeneDx by 270,700.0% during the first quarter. NewEdge Advisors LLC now owns 2,708 shares of the company’s stock worth $240,000 after purchasing an additional 2,707 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of GeneDx by 67.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 28,224 shares of the company’s stock worth $2,500,000 after purchasing an additional 11,375 shares during the period. Finally, Chung Wu Investment Group LLC grew its stake in shares of GeneDx by 8.2% in the second quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company’s stock worth $305,000 after purchasing an additional 250 shares during the last quarter. 61.72% of the stock is owned by institutional investors.

GeneDx Trading Up 2.9%

NASDAQ WGS opened at $99.01 on Tuesday. The business’s fifty day moving average is $132.47 and its 200-day moving average is $125.01. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of 1,100.11 and a beta of 2.01. GeneDx has a one year low of $55.17 and a one year high of $170.87.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.